Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 8,383 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: serum sample Clear all

Conditions: Corneal Neovascularization
Interventions: Ranibizumab; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 110 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cannabis Smoking, Oxidative Stress
Interventions: Bronchoscopy, Chest X-ray, Venipuncture, Intravenous Catheter; Procedure · Radiation
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hematologic Malignancies
Interventions: Nivolumab; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Mantle Cell Lymphoma, Lymphoma
Interventions: Bortezomib, Rituximab, Cyclophosphamide, Mesna, G-CSF; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelodysplastic Disorders, Leukemia, Multiple Myeloma, Plasma Cell Dyscrasia, Lymphoproliferative Disorders
Interventions: FLUDARABINE, CAMPATH 1H, FK50, Stem Cell Collection and Infusion; Drug · Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 2
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: CD4-IgG; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Stanford, California • Seattle, Washington

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Standard Steroid Treatment, The Standard Steroid Treatment, Plasma Exchange and rituximab; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: Danville, Pennsylvania • Philladelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more

Conditions: Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed, Colorectal Cancer (CRC)-Enrollment Completed, Renal Cell Carcinoma (RCC) (Phase ll Only), Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed
Interventions: Combination of varlilumab and nivolumab; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 19
States / cities: Tucson, Arizona • Palo Alto, California • San Francisco, California + 13 more

Conditions: Lymphoma
Interventions: rituximab, tositumomab, cyclophosphamide, doxorubicin, prednisone, vincristine, tositumomab; Biological · Drug · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 114
States / cities: Mobile, Alabama • Tucson, Arizona • Alton, Illinois + 77 more

Conditions: Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma, Grade III Meningioma, Recurrent Meningioma, Supratentorial Meningioma
Interventions: Bevacizumab, Electric Field Therapy, NovoTTF-200A Device, Quality-of-Life Assessment; Biological · Procedure · Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 8
States / cities: Santa Monica, California • Miami, Florida • Atlanta, Georgia + 5 more

Conditions: Plaque Psoriasis
Interventions: ABP 654, Ustekinumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 34
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 30 more

Conditions: Emphysema, Alpha 1-antitrypsin Deficiency (AATD)
Interventions: Prolastin-C, 60 mg/kg, Prolastin-C, 120 mg/kg; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Gainesville, Florida • Miami, Florida • Philadelphia, Pennsylvania + 2 more

Conditions: Neural Tube Defects, Anemia, Leukemia, Myeloid, Bone Marrow Transplant Failure, Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders
Interventions: CIK cells, Cyclosporine, Mycophenolate Mofetil, Thymoglobulin, Total Lymphoid Irradiation (TLI); Drug · Radiation
Lead sponsor: Everett Meyer; Other
Eligibility: 50 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Head and Neck Neoplasms
Interventions: bevacizumab; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Ocular Cicatricial Pemphigoid
Interventions: Rituximab; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Cancer
Interventions: trastuzumab, paclitaxel; Biological · Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: ICU Anemia, Functional Iron Deficiency
Interventions: Ferric carboxymaltose, Iron sucrose; Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Infertility, Female, Deferred Childbearing
Interventions: Investigational Oocyte Cryopreservation; Procedure
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Photoaging, Wrinkle
Interventions: Cleansing Lotion, Facial Moisturizer, Sunscreen SPF 40+; Other
Lead sponsor: Revision Skincare; Industry
Eligibility: 30 Years to 60 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: West Chester, Pennsylvania

Conditions: Male Hypogonadism
Interventions: Oral testosterone undecanoate; Drug
Lead sponsor: Clarus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 27
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 22 more

Conditions: Adult Primary Liver Cancer, Hepatitis C Infection
Interventions: S-adenosyl-L-methionine disulfate p-toluene-sulfonate, placebo, laboratory biomarker analysis, immunoenzyme technique, high performance liquid chromatography; Drug · Other
Lead sponsor: Chao Family Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 5
States / cities: Tucson, Arizona • Long Beach, California • Los Angeles, California + 2 more

Conditions: Non-small Cell Lung Cancer, Adenocarcinoma, Stage IV
Interventions: Rigosertib, Nivolumab; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoma
Interventions: filgrastim, rituximab, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 104
States / cities: Palo Alto, California • Fort Collins, Colorado • Jacksonville, Florida + 69 more

Conditions: Breast Cancer, Breast Carcinoma, Cancer of Breast, Malignant Tumor of Breast
Interventions: Palbociclib, Letrozole, Fulvestrant, Optional research biopsy, Goserelin, Research blood draw, Circulating tumor cell blood draw, Tumor biopsy (optional); Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 2
States / cities: St Louis, Missouri • Lincoln, Nebraska

Search by objective public record fields.

Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery

Chronic Cannabis Smoking, Oxidative Stress and the Pulmonary Innate Immune Response

Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies

Study of Bortezomib in Combination With Cyclophosphamide and Rituximab

Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H

A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related Complex

A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

Pilot Study for Locally Advanced Head and Neck Cancer

Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid

Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2

Randomized Study Comparing Ferric Carboxymaltose to Iron Sucrose to Treat Fe Deficiency in the Surgically Critically Ill

Investigational Oocyte Cryopreservation for Medical and Non Medical Indications

A Clinical Study to Evaluate the Long-Term Efficacy and Tolerability of a Daily Anti-Aging Daily Serum

Safety and Efficacy Trial of Testosterone Undecanoate

Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection

Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer